Agency: | DEPT OF DEFENSE |
---|---|
State: | Texas |
Type of Government: | Federal |
FSC Category: |
|
NAICS Category: |
|
Posted Date: | May 15, 2023 |
Due Date: | Jun 15, 2023 |
Solicitation No: | HT9402-23-Q-9301 |
Bid Source: | Please Login to View Page |
Contact information: | Please Login to View Page |
Bid Documents: | Please Login to View Page |
Procurement Technical Assistance Centers (PTACs) are an official government contracting resource for small businesses. Find your local PTAC (opens in new window) for free government expertise related to contract opportunities.
The Department of Defense (DoD) is required by law (10 U.S.C. ยง 1074g) toestablish an eff ective, eff icient, integrated pharmacy benefits program for theMilitary Health System (MHS) which includes the purchase pharmaceuticalagents. The law and implementing regulation (32 CFR Section 199.21) describethe process by which the DoD Pharmacy and Therapeutics (P&T) Committee willconsider the relative clinical eff ectiveness and relative cost eff ectiveness ofpharmaceutical agents in a therapeutic class in recommending the selection ofagents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, theclassification of a pharmaceutical agent as generic, formulary, Basic CoreFormulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior tothe scheduled P&T Committee meeting, a Request for Quotation (RFQ) forpharmaceutical agents within Drug Classes identified for placement on the UFhas been issued to obtain quotes from industry. The Defense Health Agency mayaward Uniform Formulary Blanket Purchase Agreements (UF BPA) and theUniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: August 2023: The following drug classes/subclass will be reviewed:
a. Luteinizing Hormone-Releasing Hormone Agonists-Antagonists โ Subclass: Central Precocious Puberty Agents
Fensolvi
Lupron Depot-Ped
b. Luteinizing Hormone-Releasing Hormone Agonists-Antagonists โ Subclass: Endometriosis /Fibroids Agent
Lupron Depot 3.75mg & 11.25mg
Myfembree
Oriahnn
Orilissa
c. Luteinizing Hormone-Releasing Hormone Agonists-Antagonists โ Subclass: Prostate Cancer Agents
Camcevi
Eligard
Firmagon
Lupron Depot 7.5mg, 22.5mg, 30mg, & 45mg
Leuprolide Acetate Injection Depot 22.5mg
Orgovyx
d. White Blood Cell Stimulants Subclass: Filgrastim
Granix
Neupogen
Nivestym
Releuko
Zarxio
e. White Blood Cell Stimulants Subclass: Pegfilgrastim
Fulphila
Fylnetra
Neulasta
Neulasta OnPro
Nyvepria
Stimufend
Udenyca
Ziextenzo
The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions, important deadlines, and points of contact are in document, RFQHT9402-23-Q-9301.
Pre-proposal teleconference is on May 10, 2023, details are stated in Part 2.5. Pre-proposal teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.
Apr 20, 2023 | [Solicitation (Original)] Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program |
Jun 14, 2023 | [Solicitation (Updated)] Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program |
With Free Trial, you can:
You will have a full access to bids, website, and receive daily bid report via email and web.
Follow Dental Handpieces - William Beaumont Army Medical Center Active Contract Opportunity Notice
Federal Agency
Bid Due: 6/16/2024
Follow 6550--Urinalysis Cost Per Reportable Result (CPRR) Active Contract Opportunity Notice ID 36C25724Q0560
VETERANS AFFAIRS, DEPARTMENT OF
Bid Due: 5/22/2024
Status Ref# Project Close Date Dayes Left Action Open 24/0130 ITB - Ditch
Harris County
Bid Due: 5/06/2024
Bid Information Type Competitive Sealed Bid Status Issued Number 110LR-24 (Jerseys for City
City of Irving
Bid Due: 5/06/2024